Is Vera Therapeutics, Inc. (VERA) a Buy, Sell, or Hold?
Vera Therapeutics, Inc.
NASDAQ:VERA
$43.13 USD
$1.63 (3.93%)
- Volume
- 2.59M
- Average Volume
- 1.54M
- Market Capitalization
- $3.1B
- P/E Ratio
- -7.79
- Dividend Yield
- 0.00%
- Price Target
- $90.00
- Year High
- $56.05
- Year Low
- $19.07
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $13.64
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Gary Barrera |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | VERA |
| CUSIP | 92337R101 |
| CIK | 0001831828 |
| Web | https://veratx.com |
| Phone | 650 770 0077 |
| Currency | USD |
| Employees | 249 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.15 |
| Payout Ratio | 0.00 |
| Current Ratio | 13.64 |
| Quick Ratio | 13.64 |
| Cash Ratio | 2.53 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -4.11 |
| Price / Cash Flow | -10.54 |
| Price / Book | 6.17 |
Price Target and Rating
| Average Stock Price Forecast | $90.00 |
| High Stock Price Forecast | $125.00 |
| Low Stock Price Forecast | $43.00 |
| Forecast Upside/Downside | -52.08% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 14 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-4.66 |
| Trailing P/E Ratio | -7.79 |
| PEG Ratio | 0.16 |
| P/E Growth | 0.16 |
| Net Income | $-299.62M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -74.86% |
| Return on Assets | -59.34% |
Financials Score
| AltmanZ Score | 11.86 |
| Piotroski Score | 1.00 |
| Working Capital | 570.65M |
| Total Assets | 621.74M |
| Ebit | -357.67M |
| Market Cap | 2.98B |
| Total Liabilities | 122.04M |
Poll Results
About Vera Therapeutics, Inc. (NASDAQ:VERA) Stock
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020. ...
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch
2026-07-11 14:02:52
Vera Therapeutics NASDAQ: VERA said the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA, or atacicept-vymj, for adults with primary IgA nephropathy at risk for disease progression.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-10 16:05:00
BRISBANE, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on July 6, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 32,100 shares of Class A common stock and restricted stock units (RSUs) underlying 16,050 shares of Class A common stock to eight (8) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).
2026-07-09 08:00:00
BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer position.
2026-07-07 19:12:27
Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy Transcript
US FDA approves Vera's kidney disease drug
2026-07-07 12:42:15
The U.S. Food and Drug Administration has approved Vera Therapeutics' drug to treat patients with a potentially life-threatening kidney disease, the regulator said on Tuesday, sending its shares up 6.2% in afternoon trading.
2026-07-07 12:37:00
TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers at the source of IgA nephropathy (IgAN).1,2 The TRUTAKNA dose is 150 mg injected subcutaneously once weekly, self-administered via an autoinjector by patients at home.1 Investor webcast is scheduled for July 7 at 4:30 pm EDT. A Media Snippet accompanying this announcement is available by clicking on this link.
What's Going on with Vera Therapeutics Stock on Monday?
2026-07-06 11:39:51
Investors are closely watching Vera Therapeutics Inc. (NASDAQ:VERA) as the company awaits the U.S. Food and Drug Administration (FDA) decision for its rare kidney disease drug.
3 Biotech Firms With Major Potential Catalysts in the Coming Months
2026-06-23 17:35:11
As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future. For these smaller players, one strong trial readout or FDA approval can mean the difference between a breakout and a bust.
Frequently Asked Questions
-
What is the current Vera Therapeutics, Inc. (VERA) stock price?
-
Vera Therapeutics, Inc.(NASDAQ:VERA) stock price is $43.13 in the last trading session. During the trading session, VERA stock reached the peak price of $56.05 while $19.066 was the lowest point it dropped to. The percentage change in VERA stock occurred in the recent session was 3.93% while the dollar amount for the price change in VERA stock was $1.63.
-
VERA's industry and sector of operation?
-
The NASDAQ listed VERA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of VERA?
-
S. Sandra Park | Senior Vice President of Legal, Healthcare,Commercial Law, Compliance & Operations
Sean Grant | Chief Financial Officer
Debra Charlesworth | Vice President of Corporate Communications
Emma Haywood | Vice President of Marketing
Jane Wright-Mitchell | Chief Legal Officer & Secretary -
How many employees does VERA have?
-
Number of VERA employees currently stands at 249. VERA operates from 8000 Marina Boulevard, Brisbane, CA 94005, US.
-
Link for VERA official website?
-
Official Website of VERA is: https://veratx.com
-
How do I contact VERA?
-
VERA could be contacted at phone #650 770 0077 and can also be accessed through its website. VERA operates from 8000 Marina Boulevard, Brisbane, CA 94005, US.
-
How many shares of VERA are traded daily?
-
The average number of VERA shares traded daily for last 3 months was 1.54M.
-
What is the market cap of VERA currently?
-
The market value of VERA currently stands at $3.1B with its latest stock price at $43.13